Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 18, 2009

Formatech to Fill and Finish One Lot of KAI Pharmaceuticals’ SHPT Drug at No Charge

  • KAI Pharmaceuticals’ KAI-4169 will be the second clinical candidate to receive Formatech’s manufacturing services under its Fillanthropy program. Under this program, Formatech will donate the services required to aseptically fill and finish one lot of the drug product for use in support of KAI’s upcoming clinical trials.

    KAI-4169 is being evaluated for use in the treatment of secondary hyperparathyroidism (SHPT) in kidney disease patients. Formatech plans to complete the production run of KAI-4169 in the first quarter of 2010.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »